Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998641 | 1.00 | DRD3 (0.44) | DRD3DRD2BRD4CREBBPNPC1 | |
| SCHEMBL13998639 | 1.00 | DRD3 (0.44) | DRD3DRD2BRD4CREBBPNPC1 | |
| SCHEMBL14490658 | 0.83 | DRD3 (0.44) | DRD3DRD2ADORA2ACYP2D6TSHR | |
| SCHEMBL8259536 | 0.83 | DRD3 (0.44) | DRD3DRD2ADORA2ACYP2D6TSHR | |
| SCHEMBL14490659 | 0.83 | DRD3 (0.44) | DRD3DRD2ADORA2ACYP2D6TSHR | |
| SCHEMBL12891737 | 0.82 | DRD2 (0.44) | DRD3DRD2RAB9AKDM4EALDH1A1 | |
| SCHEMBL8267166 | 0.82 | DRD2 (0.55) | DRD3DRD2RAB9AKDM4EALDH1A1 | |
| SCHEMBL12891728 | 0.82 | DRD2 (0.55) | DRD3DRD2RAB9AKDM4EALDH1A1 | |
| SCHEMBL30666578 | 0.82 | DRD2 (0.44) | DRD3DRD2RAB9AKDM4EALDH1A1 | |
| SCHEMBL12891735 | 0.82 | DRD2 (0.55) | DRD3DRD2RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11911381-B2 | Optically active azabicyclo ring derivative | Sumitomo Pharma Co., Ltd. (JP) | 2024-02-27 | — | — | US | disclosed |
| EP-4219479-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| US-11369605-B2 | Optically active azabicyclo ring derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-28 | — | — | US | disclosed |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
| WO-2022063197-A1 | PYRIMIDINE CARBOXAMIDE COMPOUND AND APPLICATION THEREOF | 上海美悦生物科技发展有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-20210338668-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-11-04 | — | — | US | disclosed |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3835304-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| US-7348333-B2 | Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. (FR) | 2008-03-25 | — | — | US | disclosed |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA S.A. | 2008-01-24 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| WO-2006004880-A2 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | DRD3 1546/4885DRD2 2063/4885BRD4 521/4885 |
| US-11369605-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | DRD3 3698/4885DRD2 3556/4885BRD4 133/4885 |
| US-11911381-B2 | Optically active azabicyclo ring derivative | MLLT3, MEN1, MLLT1 | DRD3 3316/4885DRD2 3082/4885BRD4 117/4885 |
| US-20080021055-A1 | Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists | ADGRF1, ADGRE5, CALCR | DRD3 781/4885DRD2 663/4885BRD4 2760/4885 |
| US-20210198283-A1 | OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVE | MLLT3, MLLT1, MEN1 | DRD3 1047/4885DRD2 1911/4885BRD4 60/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | DRD3 1744/4885DRD2 3101/4885BRD4 2355/4885 |
| US-11325921-B2 | Optically active crosslinked cyclic secondary amine derivative | MLLT3, MEN1, MLLT1 | DRD3 3693/4885DRD2 4157/4885BRD4 92/4885 |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | DRD3 1155/4885DRD2 634/4885BRD4 384/4885 |
| US-20210338668-A1 | OPTICALLY ACTIVE AZABICYCLO RING DERIVATIVE | MLLT3, MEN1, MLLT1 | DRD3 3698/4885DRD2 3556/4885BRD4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.